AVTX
Avalo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.07
−2.48%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$7.49
From 52W high−69.09%
Volume1.38M
Market cap$379.16M
P/E (TTM)—
P/S (TTM)6426.5x
Div yield—
Key dataNov 4, 2026
Open
$7.49
From 52W high
−69.09%
Volume
1.38M
Market cap
$379.16M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
22.9
MomentumView details →
1D Return
−2.48%
YTD Return
−61.67%
SummaryUpdated Jun 1, 2026
Avalo Therapeutics, Inc. (NASDAQ:AVTX) is a clinical-stage precision medicine company founded in 2011 and headquartered in Rockville, Maryland. Originally incorporated as Cerecor Inc., the company rebranded to Avalo Therapeutics in August 2021 to better reflect its focus on developing targeted therapeutics. The company went public in October 2015 and has since evolved into a biotechnology firm specializing in treatments for immunology, immuno-oncology, and rare genetic diseases where significant unmet medical needs exist.
Similar companies
Latest newsMore news →
Avalo Therapeutics, Inc. reported that its phase 3 FURVENT trial of furmonertinib did not meet its primary progression-free-survival endpoint in previously untreated patients with EGFR exon 20 insertion non-small-cell lung cancer.29d agoAvalo Therapeutics announced it will present late-breaker oral and poster data at the EADV Congress 2026 in Vienna, Austria, from September 30 to October 3, 2026.42d ago